PARP Inhibitor Maintenance in Newly Diagnosed Ovarian Cancer: Key Questions, Answers, and Insights 

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Gynecologic Cancer Education: PARP Inhibitor TherapyПодробнее

PARP Inhibitors: New Insights & Future of Ovarian Cancer TreatmentПодробнее

Precision Medicine in Ovarian Cancer With PARP Inhibitor Therapy and Companion DiagnosticsПодробнее

PARP inhibitor rechallenging in ovarian cancerПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Epithelial Ovarian CancerПодробнее

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее

Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Olaparib + beva maintenance in newly diagnosed, advanced ovarian cancer (OC) treated with PCh + bevПодробнее

The PARP Revolution: How PARP inhibitors are changing the landscape of ovarian cancer treatmentПодробнее

PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChatПодробнее

Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian CancerПодробнее

Ongoing Clinical Trials with PARP Inhibitors in Ovarian CancerПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

Webinar: PARP Inhibitors and Ovarian CancerПодробнее

Targeted Therapy in Newly Diagnosed Advanced Ovarian CancerПодробнее

The Advanced Ovarian Cancer Treatment Palette: Candid Conversations on PARP InhibitorsПодробнее

Ovarian Cancer: PARP Inhibitors and Beyond (Webinar) May 8th World Ovarian Cancer DayПодробнее